STAT — Reporting from the frontiers of health and medicine
- First Opinion Containing Covid-19 requires rapid tests that are highly sensitive to infections. Why is the FDA asking for something different?
- Pharmalot Institutional investors urge pharma boards to tie executive compensation to global Covid vaccine equity
- First Opinion Recognizing obesity as a disease, not a choice, is a step toward health equity
- Health Study raises doubts about rapid Covid tests’ reliability in early days after infection
- Health CDC recommends teens 12 to 17 should receive a Covid-19 booster shot
- First Opinion Containing Covid-19 requires rapid tests that are highly sensitive to infections. Why is the FDA asking for something different?
- Pharmalot Institutional investors urge pharma boards to tie executive compensation to global Covid vaccine equity
- First Opinion Recognizing obesity as a disease, not a choice, is a step toward health equity
- Health Study raises doubts about rapid Covid tests’ reliability in early days after infection
- Health CDC recommends teens 12 to 17 should receive a Covid-19 booster shot
Exclusive analysis of biotech, pharma, and the life sciences
-
Applied Therapeutics tried to muzzle short sellers — but the truth still came out
-
Drug makers ring in the new year with 5% price hikes on hundreds of medicines
-
Pharmalittle: More top hospitals aren’t offering Biogen Alzheimer’s drug; Pfizer may lower Covid pill price in poor countries until supplies rise
- Health Study raises doubts about rapid Covid tests’ reliability in early days after infection
- First Opinion Confessions of a ‘human guinea pig’: Why I’m resigning from Moderna vaccine trials
- In the Lab Provocative new findings suggest a surprising cause of Down syndrome: cells linked to aging
-
- Health CDC recommends teens 12 to 17 should receive a Covid-19 booster shot
- Matt's Take The tragedy of Johnson & Johnson’s Covid vaccine
- First Opinion Containing Covid-19 requires rapid tests that are highly sensitive to infections. Why is the FDA asking for something different?
- Health The Covid-19 Tracker
- Biotech ‘It’s almost negligible’: More top hospitals aren’t offering controversial Alzheimer’s drug Aduhelm
